Preoperative Treatment with Capecitabine, Cetuximab and Radiotherapy for Primary Locally Advanced Rectal Cancer - A Phase II Clinical Trial

被引：0

作者：

Eisterer, Wolfgang ^{[1
]}

De Vries, Alexander ^{[3
]}

Oefner, Dietmar ^{[4
]}

Rabl, Hans ^{[7
]}

Koplmueller, Renate ^{[8
]}

Greil, Richard ^{[5
]}

Tschmelitsch, Joeerg ^{[9
]}

Schmid, Rainer ^{[10
]}

Kapp, Karin ^{[13
]}

Lukas, Peter ^{[2
]}

Sedlmayer, Felix ^{[6
]}

Hoefler, Gerald ^{[14
]}

Gnant, Michael ^{[11
,12
]}

Thaler, Josef ^{[8
]}

机构：

[1] Med Univ Innsbruck, Dept Internal Med 5, A-6020 Innsbruck, Austria

[2] Med Univ Innsbruck, Dept Radiooncol, A-6020 Innsbruck, Austria

[3] Feldkirch Hosp, Dept Radiotherapy & Radiooncol, Feldkirch, Austria

[4] Paracelsus Med Univ, Dept Surg, Salzburg, Austria

[5] Paracelsus Med Univ, Dept Internal Med 3, Salzburg, Austria

[6] Paracelsus Med Univ, Dept Radiooncol, Salzburg, Austria

[7] Leoben Hosp, Dept Surg, Leoben, Austria

[8] Hosp Wels Grieskirchen, Dept Internal Med 4, Wels, Austria

[9] St Veit Hosp, Dept Surg, Sankt Veit An De Glan, Austria

[10] Med Univ Vienna, Dept Radiooncol, Vienna, Austria

[11] Med Univ Vienna, Dept Surg, Vienna, Austria

[12] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria

[13] Med Univ, Dept Radiooncol, Graz, Austria

[14] Med Univ, Dept Pathol, Graz, Austria

来源：

ANTICANCER RESEARCH | 2014年 / 34卷 / 11期

关键词：

Rectal cancer; radiochemotherapy; capecitabine; cetuximab; phase II trial; METASTATIC COLORECTAL-CANCER; EXTERNAL-BEAM RADIOTHERAPY; TOTAL MESORECTAL EXCISION; NEOADJUVANT TREATMENT; IMPROVED SURVIVAL; OXALIPLATIN; IRINOTECAN; FLUOROURACIL; CHEMOTHERAPY; COMBINATION;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: To investigate the feasibility and safety of preoperative capecitabine cetuximab and radiation in patients with MRI-defined locally advanced rectal cancer LARC, cT3/T4). Patients and Methods: 31 patients with ARC were treated with cetuximab and capecitabine concomitantly with 45 Gy radiotherapy and resected by total mesorectal excision. Histopathological response and association with KRAS status was evaluated. Results: R0-resection was possible in 27 of 31 (86%) patients, No complete pathological remission was observed. Radiochemotherapy with capecitabine and cetuximab was safe to administer and diarrhea was the main toxicity. KRAS-status did not correlate to down-staging or pathological response concerning T- or N-stage. Conclusion: Neoadjuvant therapy with capecitabine and cetuximab in combination with radiotherapy did not lead to complete pathological remission. Treatment tolerability was excellent and toxicity remained low. KRAS status did not influence treatment outcomes.

引用

页码：6767 / 6773

页数：7

共 33 条

[1]

[Anonymous], 1999, 62 ICRU

[2]

[Anonymous], 2009, Common Terminology Criteria for Adverse Events (CTCAE). 4.0 ed

[3]

[Anonymous], N ENGL J MED

[4] Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer [J].

Bengala, C. ;

Bettelli, S. ;

Bertolini, F. ;

Salvi, S. ;

Chiara, S. ;

Sonaglio, C. ;

Losi, L. ;

Bigiani, N. ;

Sartori, G. ;

Dealis, C. ;

Malavasi, N. ;

D'Amico, R. ;

Luppi, G. ;

Gatteschi, B. ;

Maiorana, A. ;

Conte, P. F. .

ANNALS OF ONCOLOGY, 2009, 20 (03) :469-474

[5] NEOADJUVANT TREATMENT WITH SINGLE-AGENT CETUXIMAB FOLLOWED BY 5-FU, CETUXIMAB, AND PELVIC RADIOTHERAPY: A PHASE II STUDY IN LOCALLY ADVANCED RECTAL CANCER [J].

Bertolini, Federica ;

Chiara, Silvana ;

Bengala, Carmelo ;

Antognoni, Paolo ;

Dealis, Cristina ;

Zironi, Sandra ;

Malavasi, Norma ;

Scolaro, Tindaro ;

Depenni, Roberta ;

Jovic, Gordana ;

Sonaglio, Claudia ;

Rossi, Aldo ;

Luppi, Gabriele ;

Conte, Pier Franco .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (02) :466-472

[6] Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival [J].

Bonner, James A. ;

Harari, Paul M. ;

Giralt, Jordi ;

Cohen, Roger B. ;

Jones, Christopher U. ;

Sur, Ranjan K. ;

Raben, David ;

Baselga, Jose ;

Spencer, Sharon A. ;

Zhu, Junming ;

Youssoufian, Hagop ;

Rowinsky, Eric K. ;

Ang, K. Kian .

LANCET ONCOLOGY, 2010, 11 (01) :21-28

[7] Chemotherapy with preoperative radiotherapy in rectal cancer [J].

Bosset, Jean-Francois ;

Collette, Laurence ;

Calais, Gilles ;

Mineur, Laurent ;

Maingon, Philippe ;

Radosevic-Jelic, Ljiljana ;

Daban, Alain ;

Bardet, Etienne ;

Beny, Alexander ;

Ollier, Jean-Claude .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (11) :1114-1123

[8]

Cabebe EC, 2008, J CLIN ONCOL, V26, P15019

[9] Improved survival and reduction in local failure rates after preoperative radiotherapy -: Evidence for the generalizability of the results of Swedish Rectal Cancer Trial [J].

Dahlberg, M ;

Glimelius, B ;

Påhlman, L .

ANNALS OF SURGERY, 1999, 229 (04) :493-497

[10] Molecular Response to Cetuximab and Efficacy of Preoperative Cetuximab-Based Chemoradiation in Rectal Cancer [J].

Debucquoy, Annelies ;

Haustermans, Karin ;

Daemen, Anneleen ;

Aydin, Selda ;

Libbrecht, Louis ;

Gevaert, Olivier ;

De Moor, Bart ;

Tejpar, Sabine ;

McBride, William H. ;

Penninckx, Freddy ;

Scalliet, Pierre ;

Stroh, Christopher ;

Vlassak, Soetkin ;

Sempoux, Christine ;

Machiels, Jean-Pascal .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (17) :2751-2757

← 1 2 3 4 →